Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fluorescein Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module

NCT03279939
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Fluorescein Angiography, Indocyaine Green Angiography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054
View directory record Official record
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 22, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

NCT05312411
View directory record Official record
Conditions
Osteosarcoma
Interventions
SCRI-E2CAR_EGFRtv1, UB_TT170
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

NCT01959243
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 22, 2026, 2:34 PM EDT
Not yet recruiting Not applicable Interventional

TearCare in Young Adults

NCT07579156
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
TearCare®
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Not applicable Interventional

Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon

NCT03220711
View directory record Official record
Conditions
Colonic Dysplasia, Adenomatous Polyps, Irritable Bowel Disease
Interventions
confocal endomicroscope, Fluorescein
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Not applicable Interventional

The Use of Dye-less Cystoscopy in Assessing Urinary Tract Integrity During Hysterectomy

NCT05190939
View directory record Official record
Conditions
Hysterectomy, Cystoscopy
Interventions
water as bladder distending media, intravenous dye, No intervention
Diagnostic Test
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting Not applicable Interventional

Evaluation of the CONVIVO System

NCT05139277
View directory record Official record
Conditions
Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
Interventions
CONVIVO system, Conventional histologic evaluation
Diagnostic Test · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Not applicable Interventional Results available

Needle-Based Confocal Laser Endomicroscopy for Diagnosis of Lung Cancer in Patients With Peripheral Pulmonary Nodules

NCT05556525
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Fluorescein, Image-Guided Needle Confocal Laser Endomicroscopy, Ultrasound-Guided Transbronchial Needle Aspiration
Other · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Identification of Nerves Using Fluorescein Sodium

NCT06054178
View directory record Official record
Conditions
Pleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck, Thyroid Disease, Thyroidectomy
Interventions
Fluorescein Sodium
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

NCT00329368
View directory record Official record
Conditions
Cancer
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Springfield, Illinois • Lansing, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Early Phase 1 Interventional

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

NCT03297489
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Stage I Ovarian Cancer, Stage IA Ovarian Cancer, Stage IB Ovarian Cancer, Stage IC Ovarian Cancer, Stage II Ovarian Cancer, Stage IIA Ovarian Cancer, Stage IIB Ovarian Cancer, Stage IIC Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)

NCT01778920
View directory record Official record
Conditions
Lung and Pleural Malignancies, Neoplasms, Nodules, Adenocarcinoma
Interventions
EC17 imaging contrast agent
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Confocal Laser Probe to Treat Barrett's Esophagus

NCT02852525
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Confocal laser endomicroscopy (pCLE)
Device
Lead sponsor
Virendra Joshi
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Kenner, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Completed No phase listed Observational

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT04340505
View directory record Official record
Conditions
Uveitis
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

NCT01260779
View directory record Official record
Conditions
Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory, Approved Alternative Therapy
Interventions
PV-10 (10% rose bengal disodium)
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
3
States / cities
Louisville, Kentucky • Bethlehem, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

NCT00485563
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting No phase listed Observational

Loupe-Based Intraoperative Fluorescence Imaging

NCT04780009
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Not listed
Lead sponsor
Guoqiang Yu
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting No phase listed Observational

Kidney Precision Medicine Project

NCT04334707
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
Interventions
Kidney Biopsy, MRI, Retina Scan
Procedure · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Not applicable Interventional Results available

Advanced Gastrointestinal Endoscopic Imaging

NCT01034670
View directory record Official record
Conditions
Gastrointestinal Diseases, Gastric (Stomach) Cancer, Gastrointestinal Stromal Tumor (GIST)
Interventions
Dual axis endoscopic microscope, wide field fluorescence system, CellVizio, fluorescent Peptide, fluorescein, indocyanine green
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting No phase listed Observational

Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes

NCT07270133
View directory record Official record
Conditions
Diabetic Retinal Disease
Interventions
Visual Acuity, Reading Speed, Visual Field testing, Contrast sensitivity, Electroretinography (ERG) and pupillography in light- and dark-adapted states, Ultrawide field-color photograph, Ultrawide field-Fluorescein angiogram, Optical coherence tomography, Optical coherence tomography- Angiography
Diagnostic Test · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Augusta, Georgia • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion

NCT00815360
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide, macular laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 22, 2026, 2:34 PM EDT